title: Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
abstract: We previously reported that treatment with 160mg/d of lurasidone improved cognitive performance in a manner superior to placebo, quetiapine XR 600mg/d, and lurasidone 80mg/d, based on a 6-week randomized trial of patients with an acute exacerbation of schizophrenia. The objective of this post-hoc analysis was to explore the cognitive and functional performance of patients whose final doses of lurasidone were 40/80mg/d, 120mg/d, and 160mg/d compared to quetiapine XR 200-800mg/d (QXR) during a 6-month, double-blind continuation study that followed a short-term trial. Subjects who received final doses of lurasidone 120mg/d (n=77) and 160mg/d (n=49) showed significantly greater improvement in overall cognitive performance compared to QXR (n=85) at week 32 (month 6 of the extension study), while those on last doses of 40/80mg/d (n=25) showed a trend towards significance at week 32. Mean changes in neurocognitive composite z-score from pre-treatment baseline were significant for the 3 lurasidone final dose groups at both weeks 19 and 32, with composite change scores of z=1.53, z=1.43, and z=1.34 for the lurasidone 40/80mg/d, 120mg/d, and 160mg/d, respectively, at week 32. In contrast, the composite change score was not statistically significant in the overall quetiapine group (z=0.46), with none of the individual quetiapine doses showing any significant improvement. Functional capacity scores improved in all treatment groups. Our findings indicate improved cognitive performance in patients treated with each of the flexible doses of lurasidone 40-160mg/d, compared to quetiapine XR 200-800mg/d. All doses of lurasidone were superior to all doses of quetiapine for cognitive performance.
authors.affiliation: University of Miami Miller School of Medicine, Miami, FL, USA.
authors.forename: Philip D
authors.initials: PD
authors.lastname: Harvey
authors.affiliation: COS & Associates Ltd., Central District, Hong Kong.
authors.forename: Cynthia O
authors.initials: CO
authors.lastname: Siu
authors.affiliation: Sumitomo Dainippon Pharma Co., Ltd., Chuo-ku, Tokyo, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ogasa
authors.affiliation: Sunovion Pharmaceuticals Inc., Fort Lee, NJ USA.
authors.forename: Antony
authors.initials: A
authors.lastname: Loebel
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D016018:Least-Squares Analysis; D000069056:Lurasidone Hydrochloride / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate / Q000008:administration & dosage; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D000069348:Quetiapine Fumarate; D000069056:Lurasidone Hydrochloride
keywords: Antipsychotics; Lurasidone; Neurocognition; Quetiapine